Database→Argireline

Tier 2-3SkinAnti-agingPREMIUM

Argireline

Argireline (Acetyl Hexapeptide-8 / Ac-EEMQRR-NH2; formerly Acetyl Hexapeptide-3)

Cosmetic ingredient only. Regulated in the USA by FDA as a cosmetic, not a drug. No drug approval exists or has been sought. Not WADA-listed. No compounding restrictions apply as it is not used as an injectable drug. Sold under the trade name Argireline by Lipotec (now Lubrizol). Not a scheduled or controlled substance.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Argireline (Acetyl Hexapeptide-8) is a synthetic cosmetic hexapeptide developed by Lipotec in 2002, designed to mimic the N-terminal end of SNAP-25 and competitively inhibit SNARE complex formation at the neuromuscular junction, reducing facial muscle contraction and expression wrinkles. The cellular mechanism is confirmed in vitro. The Wang 2013 RCT (n=60) showed 48.9% subjective wrinkle improvement versus 0% placebo at 4 weeks. However, the Kraeling 2015 in vitro penetration study (conducted at FDA laboratories) found zero Argireline detectable in human skin dermis after topical application. Whether wrinkle improvements reflect the claimed neuromuscular mechanism or surface hydration effects is an unresolved scientific controversy. All major clinical studies were conducted by or affiliated with Lipotec.

🔒

Full Profile: Premium Members Only

The complete Argireline profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use